Alfonso Duenas Gonzalez

Alfonso Duenas Gonzalez

Alfonso Duenas Gonzalez, PhD
Unit of Biomedical Research on Cancer,nstituto de Investigaciones Biomedicas UNAM, Instituto


Alfonso Duenas-González M.D. Ph.D, graduated from the Faculty of Medicine, University of Guadalajara Mexico, specialized in Internal Medicine at the National Institute of Medical Sciences and Nutrition, Mexico and Medical Oncology at the National CancerInstitute of Mexico. He earned his Doctorate degree at the University of Salamanca, Spain and did post-­â€doctoral studies at the Sunny brook Health Science Centre at the University of Toronto. He was the head of Research at the National Cancer Institute of Mexico for several years and currently is a full time researcher at both, Institute of Biomedical Research of the National Autonomous University of Mexico and the National Cancer Institute. He has pioneered Translational Research studies in Cancer Epigenetics and Drug Repositioning as well as conducted clinicaltrials in cervical cáncer treatment. He is also interested in the study of the biological significance of circulating DNA and its diagnostic applications for early detection of cancer as well as in the metabolic therapy of cancer and cancergenetics. He has served in the editorial boards of several international scientific biomedical journals, and recently has been appointed as the Editor-in-Chief of the World Journal of Translational Medicine. He also has served as a reviewer of researchpapers in a number of recognized journals, and international grant agencies as well as Scientific Advisor and speaker for Pharmaceutical Industry. He has authored more than 100 scientific articles and has edited chapters and books in the field of Medicine. He has lectured anumber of conferences in well-known international meetings and has conducted the preclinical and clinical development of cáncer drugs. He has trainedtens of postgraduatestudents and he has been therecipient of several important awards in Mexico.

Research Interest

Cancerepigenetics and drugrepositioning
Circulating DNA
Cervical Cancer